Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
Anish Patel, the Chief Operating Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1 billion market cap biotechnology company with a GOOD financial health rating according to InvestingPro, recently sold shares of the company’s stock, according to a filing with the Securities and Exchange Commission. The transaction, executed on March 7, involved the sale of 6,667 shares of common stock at a weighted average price of approximately $21.44 per share, totaling $142,936.
The sale was conducted under a Rule 10b5-1 trading plan, which had been adopted by Patel and The Patel / Dong Family Trust on September 30, 2024. Following this transaction, Patel retains indirect ownership of 323,310 shares through the trust. The shares sold are held by The Patel / Dong Family Trust, for which Patel serves as trustee.
In other recent news, Enliven Therapeutics has garnered attention from analysts with new coverage and ratings. BTIG initiated coverage with a Buy rating, setting a price target of $42.00, emphasizing the company’s focus on developing targeted tyrosine kinase inhibitors (TKIs) for cancer treatment. The firm highlighted Enliven’s advancements in TKIs for both solid and liquid cancers, which are expected to improve safety, tolerability, and efficacy. Meanwhile, Clear Street also assigned a Buy rating to Enliven Therapeutics, with a price target of $36.00, citing the company’s development of a potentially best-in-class drug for chronic myeloid leukemia (CML). Both analyst firms expressed confidence in Enliven’s potential to reach significant milestones in the next 12 to 18 months, which could impact the company’s standing in the TKI market. Enliven’s team, known for their successful track record in drug development, is expected to release key clinical data in the coming months. These developments are seen as pivotal for the company’s future growth and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.